December 2019 - Volume 44 - Issue 12 - Contributor Index

Alphabetical Search
D
E
G
H
I
K
N
O
P
Q
S
T
V
X

Exploring nurse vs. NP disaster response competencies

Adelman, Deborah S.; Fant, Catherine; Wood, Laura; More

The Nurse Practitioner. 44(12):42-48, December 2019.

This second installment of the Disaster Response Series covers the nurse competencies for disaster response outlined by the International Council of Nurses and the World Health Organization. The authors explore how NP disaster response competencies from the National Organization of Nurse Practitioner Faculties align with nurse competencies.

Drug updates and approvals: 2019 in review

Crump, Lauren Hartsell; Benfield, Miranda; Ramey, Caleb; More

The Nurse Practitioner. 44(12):21-32, December 2019.

In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol(Duaklir Pressair); and siponimod (Mayzent).

Hypertension management in patients with chronic kidney disease

Liddell, Toddra S.; Bassett, Robin; Link, Denise K.

The Nurse Practitioner. 44(12):34-40, December 2019.

Managing hypertension, especially when accompanied by chronic kidney disease, is challenging. These different but related conditions are complicated by differing guidelines. NPs can safely prescribe antihypertensive treatments, which reduce hypertension and the risk of associated comorbidities, such as kidney failure, stroke, myocardial infarction, and vascular disease.

Drug updates and approvals: 2019 in review

Crump, Lauren Hartsell; Benfield, Miranda; Ramey, Caleb; More

The Nurse Practitioner. 44(12):21-32, December 2019.

In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol(Duaklir Pressair); and siponimod (Mayzent).

Author:
Brown, Jenna BS

Drug updates and approvals: 2019 in review

Crump, Lauren Hartsell; Benfield, Miranda; Ramey, Caleb; More

The Nurse Practitioner. 44(12):21-32, December 2019.

In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol(Duaklir Pressair); and siponimod (Mayzent).

Drug updates and approvals: 2019 in review

Crump, Lauren Hartsell; Benfield, Miranda; Ramey, Caleb; More

The Nurse Practitioner. 44(12):21-32, December 2019.

In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol(Duaklir Pressair); and siponimod (Mayzent).

Exploring nurse vs. NP disaster response competencies

Adelman, Deborah S.; Fant, Catherine; Wood, Laura; More

The Nurse Practitioner. 44(12):42-48, December 2019.

This second installment of the Disaster Response Series covers the nurse competencies for disaster response outlined by the International Council of Nurses and the World Health Organization. The authors explore how NP disaster response competencies from the National Organization of Nurse Practitioner Faculties align with nurse competencies.

Hypertension management in patients with chronic kidney disease

Liddell, Toddra S.; Bassett, Robin; Link, Denise K.

The Nurse Practitioner. 44(12):34-40, December 2019.

Managing hypertension, especially when accompanied by chronic kidney disease, is challenging. These different but related conditions are complicated by differing guidelines. NPs can safely prescribe antihypertensive treatments, which reduce hypertension and the risk of associated comorbidities, such as kidney failure, stroke, myocardial infarction, and vascular disease.

Hypertension management in patients with chronic kidney disease

Liddell, Toddra S.; Bassett, Robin; Link, Denise K.

The Nurse Practitioner. 44(12):34-40, December 2019.

Managing hypertension, especially when accompanied by chronic kidney disease, is challenging. These different but related conditions are complicated by differing guidelines. NPs can safely prescribe antihypertensive treatments, which reduce hypertension and the risk of associated comorbidities, such as kidney failure, stroke, myocardial infarction, and vascular disease.

Drug updates and approvals: 2019 in review

Crump, Lauren Hartsell; Benfield, Miranda; Ramey, Caleb; More

The Nurse Practitioner. 44(12):21-32, December 2019.

In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol(Duaklir Pressair); and siponimod (Mayzent).

Drug updates and approvals: 2019 in review

Crump, Lauren Hartsell; Benfield, Miranda; Ramey, Caleb; More

The Nurse Practitioner. 44(12):21-32, December 2019.

In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol(Duaklir Pressair); and siponimod (Mayzent).

Author:
Ramey, Caleb

Drug updates and approvals: 2019 in review

Crump, Lauren Hartsell; Benfield, Miranda; Ramey, Caleb; More

The Nurse Practitioner. 44(12):21-32, December 2019.

In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol(Duaklir Pressair); and siponimod (Mayzent).

APRN transition to practice: Program development tips

Urbanowicz, Janet

The Nurse Practitioner. 44(12):50-55, December 2019.

Leaving the comfort zone of being an experienced RN for a new career as an inexperienced advanced practice registered nurse (APRN) is one of the greatest difficulties of the APRN transition to practice. To date, very few formal APRN residency or fellowship transition programs exist. Practicing APRNs can advocate for a formal transition program in their organizations.

Exploring nurse vs. NP disaster response competencies

Adelman, Deborah S.; Fant, Catherine; Wood, Laura; More

The Nurse Practitioner. 44(12):42-48, December 2019.

This second installment of the Disaster Response Series covers the nurse competencies for disaster response outlined by the International Council of Nurses and the World Health Organization. The authors explore how NP disaster response competencies from the National Organization of Nurse Practitioner Faculties align with nurse competencies.

Author:
Yang, Sebin BA

Drug updates and approvals: 2019 in review

Crump, Lauren Hartsell; Benfield, Miranda; Ramey, Caleb; More

The Nurse Practitioner. 44(12):21-32, December 2019.

In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol(Duaklir Pressair); and siponimod (Mayzent).

Exploring nurse vs. NP disaster response competencies

Adelman, Deborah S.; Fant, Catherine; Wood, Laura; More

The Nurse Practitioner. 44(12):42-48, December 2019.

This second installment of the Disaster Response Series covers the nurse competencies for disaster response outlined by the International Council of Nurses and the World Health Organization. The authors explore how NP disaster response competencies from the National Organization of Nurse Practitioner Faculties align with nurse competencies.